Targeted Coaching to Improve Osteoporosis Therapy Adherence: A Single Arm Variation of the C-STOP Study.

Q2 Medicine Journal of Bone Metabolism Pub Date : 2024-02-01 Epub Date: 2024-02-29 DOI:10.11005/jbm.2024.31.1.13
Carrie Ye, Finlay A McAlister, Debbie Bellerose, Meng Lin
{"title":"Targeted Coaching to Improve Osteoporosis Therapy Adherence: A Single Arm Variation of the C-STOP Study.","authors":"Carrie Ye, Finlay A McAlister, Debbie Bellerose, Meng Lin","doi":"10.11005/jbm.2024.31.1.13","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In this pre-planned variation of the Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP) trial, we investigated whether adherence-specific coaching by the case manager (CM) further improved the adherence and persistence rates compared to those seen in the C-STOP trial.</p><p><strong>Methods: </strong>We conducted a prospective observational cohort study of community-dwelling adults 50 years or older who suffered an upper-extremity fracture and were not previously treated with osteoporosis medications, to assess whether a well-trained CM can partner with patients to improve adherence to and persistence with oral bisphosphonate intake. The primary outcome was adherence (taking > 80% of prescribed doses) to oral bisphosphonate intake at 12 months after study enrollment. Secondary outcomes included primary adherence to and 12-month persistence with oral bisphosphonate and calcium and vitamin D supplement intake at 12 months.</p><p><strong>Results: </strong>The study cohort consisted of 84 participants, of which 30 were prescribed an oral bisphosphonate. Twenty-two (73.3%) started treatment within 3 months. The adherence rate at 12 months was 77.3%. The persistence rate at 12 months was 95.5%. Of those not prescribed an oral bisphosphonate, 62.8% were taking supplemental calcium and 93.0% were taking supplemental vitamin D at 12 months. Depression was a significant predictor of 12-month non-adherence (adjusted odds ratio, 9.8; 95% confidence interval, 1.2-81.5).</p><p><strong>Conclusions: </strong>Adherence-specific coaching by a CM did not further improve the level of medication adherence achieved in the original C-STOP study. Importantly, these results can inform adherence in future intervention studies.</p>","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"31 1","pages":"13-20"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940104/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11005/jbm.2024.31.1.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In this pre-planned variation of the Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP) trial, we investigated whether adherence-specific coaching by the case manager (CM) further improved the adherence and persistence rates compared to those seen in the C-STOP trial.

Methods: We conducted a prospective observational cohort study of community-dwelling adults 50 years or older who suffered an upper-extremity fracture and were not previously treated with osteoporosis medications, to assess whether a well-trained CM can partner with patients to improve adherence to and persistence with oral bisphosphonate intake. The primary outcome was adherence (taking > 80% of prescribed doses) to oral bisphosphonate intake at 12 months after study enrollment. Secondary outcomes included primary adherence to and 12-month persistence with oral bisphosphonate and calcium and vitamin D supplement intake at 12 months.

Results: The study cohort consisted of 84 participants, of which 30 were prescribed an oral bisphosphonate. Twenty-two (73.3%) started treatment within 3 months. The adherence rate at 12 months was 77.3%. The persistence rate at 12 months was 95.5%. Of those not prescribed an oral bisphosphonate, 62.8% were taking supplemental calcium and 93.0% were taking supplemental vitamin D at 12 months. Depression was a significant predictor of 12-month non-adherence (adjusted odds ratio, 9.8; 95% confidence interval, 1.2-81.5).

Conclusions: Adherence-specific coaching by a CM did not further improve the level of medication adherence achieved in the original C-STOP study. Importantly, these results can inform adherence in future intervention studies.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
改善骨质疏松症治疗依从性的针对性辅导:C-STOP研究的单臂变异。
背景:在上肢骨折后针对骨质疏松症预防骨折的策略比较试验(C-STOP)的这一预先计划的变异试验中,我们研究了与 C-STOP 试验中的结果相比,由个案管理员(CM)提供的针对依从性的指导是否能进一步提高依从率和坚持率:我们对上肢骨折且之前未接受过骨质疏松症药物治疗的 50 岁及以上居住在社区的成年人进行了一项前瞻性观察性队列研究,以评估训练有素的个案管理员能否与患者合作,提高患者对口服双膦酸盐的依从性和持续性。研究的主要结果是入组 12 个月后口服双膦酸盐的依从性(服用处方剂量的 80% 以上)。次要结果包括口服双膦酸盐的主要依从性和12个月的持续性,以及12个月的钙和维生素D补充剂摄入量:研究队列由 84 名参与者组成,其中 30 人获得了口服双膦酸盐处方。22人(73.3%)在3个月内开始接受治疗。12个月时的坚持率为77.3%。12 个月的坚持率为 95.5%。在未获处方口服双膦酸盐的患者中,62.8% 的人在 12 个月时服用了补充钙剂,93.0% 的人服用了补充维生素 D。抑郁症是12个月未坚持治疗的重要预测因素(调整后的几率比为9.8;95%置信区间为1.2-81.5):结论:在最初的 C-STOP 研究中,由中医师提供的针对依从性的指导并没有进一步提高患者的服药依从性。重要的是,这些结果可为今后的干预研究提供指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Bone Metabolism
Journal of Bone Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.70
自引率
0.00%
发文量
23
期刊最新文献
Cross-Calibration of Bone Mineral Density and Body Composition between GE Lunar Prodigy and Hologic Horizon W Dual Energy X-Ray Absorptiometry Systems. Biomimetic Architectural Cover Accelerates Osseointegration of Titanium Implants. Effects of Various Anti-Diabetic Drugs on the Risk of Fractures in Older Women with Type 2 Diabetes Mellitus. Distribution and Characteristics of Fall Risk Index-21 Scores in Patients with Fall-Related Hip Fractures. Effects of Bone Morphogenetic Protein Agonist Small Molecule, SB4, on Osteogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1